The disclosure is based on the discovery that aberrant immune responses are contributing to the pathogenicity of CCMs in patients, and that blocking those responses treats the CCM. Described herein is a method for treating CCMs in a patient in need thereof comprising administering a therapeutically effective amount of a B-cell immunomodulation therapy to the patient.